Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Over 200 Patient Groups Call on House to Reinstate Orphan Drug Tax Credit in GOP’s Tax Reform Bill

Washington, DC, November 9, 2017 — More than 200 nonpartisan patient groups sent a letter to U.S. House of Representatives leadership, Republican and Democratic, urging policymakers not to repeal the Orphan Drug Tax Credit in the Tax Cuts and Jobs Act.

The proposed change to repeal the Orphan Drug Tax Credit would result in one-third fewer new treatments for rare diseases going forward.

Of the approximately 7,000 diseases considered rare in the U.S., only a few hundred have FDA-approved treatments.  The Orphan Drug Tax Credit gives hope to the nearly 95 percent of individuals with rare diseases who are still without a treatment.

“We urge Congress to listen carefully to their constituents and the 30 million Americans with rare diseases,” said Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), the leading independent nonpartisan and nonprofit patient advocacy group representing all people with rare diseases.

“The Orphan Drug Tax Credit,” Saltonstall continued, “is one of the most important incentives for spurring the development of therapies for individuals with rare diseases, and its repeal is wholly unacceptable.  We implore the House of Representatives to reconsider.”

NORD said rare disease advocates have sent more than 2,000 letters to Congress in support of the Orphan Drug Tax Credit since the release of the Tax Cuts and Jobs Act on Nov. 2.

The full text of the letter to Congress and the signers can be viewed here.